For example, CASP9 was predicted to be a target of sorafenib by NetTar, where the compound was used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma and the other two protein, MAPK1 and RAF1, from motif II has been found to be related to the diseases16, 43, 44. This evidence concerns the gene MAPK1 and hepatocellular carcinoma.